

1. Adjei, A.A., M. Christian, and P. Ivy, *Novel designs and end points for phase II clinical trials*. Clin Cancer Res, 2009. **15**(6): p. 1866-72.
2. Amaravadi, R.K., et al., *Principles and Current Strategies for Targeting Autophagy for Cancer Treatment*. Clin Cancer Res, 2011. **17**(4): p. 654-666.
3. Dancey, J.E., et al., *Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents*. Clin Cancer Res, 2010. **16**(6): p. 1745-55.
4. Dhani, N., et al., *Alternate endpoints for screening phase II studies*. Clin Cancer Res, 2009. **15**(6): p. 1873-82.
5. Forster, M.D., et al., *Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan*. Clin Cancer Res, 2010. **16**(6): p. 1737-44.
6. Hewitt, S.M., S.S. Badve, and L.D. True, *Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy*. Clin Cancer Res, 2012. **18**(6): p. 1524-30.
7. Ivy, S.P., et al., *Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee*. Clin Cancer Res, 2010. **16**(6): p. 1726-36.
8. LaBarge, M.A., *The difficulty of targeting cancer stem cell niches*. Clin Cancer Res, 2010. **16**(12): p. 3121-9.
9. LoRusso, P.M., S.A. Boerner, and L. Seymour, *An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics*. Clin Cancer Res, 2010. **16**(6): p. 1710-8.
10. Maitland, M.L., *Cardiovascular toxicity of new agents*. Clin Adv Hematol Oncol, 2008. **6**(9): p. 657-9.
11. Maitland, M.L., et al., *Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors*. J Natl Cancer Inst, 2010. **102**(9): p. 596-604.
12. McShane, L.M., S. Hunsberger, and A.A. Adjei, *Effective incorporation of biomarkers into phase II trials*. Clin Cancer Res, 2009. **15**(6): p. 1898-905.
13. Merchant, A.A. and W. Matsui, *Targeting Hedgehog--a cancer stem cell pathway*. Clin Cancer Res, 2010. **16**(12): p. 3130-40.
14. Meshinchi, S., et al., *Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031*. Clin Cancer Res, 2012. **18**(6): p. 1547-54.
15. O'Brien, C.A., A. Kreso, and C.H. Jamieson, *Cancer stem cells and self-renewal*. Clin Cancer Res, 2010. **16**(12): p. 3113-20.
16. Pannuti, A., et al., *Targeting Notch to target cancer stem cells*. Clin Cancer Res, 2010. **16**(12): p. 3141-52.
17. Poste, G., et al., *Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development*. Clin Cancer Res, 2012. **18**(6): p. 1515-23.
18. Rubinstein, L., et al., *Randomized phase II designs*. Clin Cancer Res, 2009. **15**(6): p. 1883-90.
19. Sargent, D.J. and J.M. Taylor, *Current issues in oncology drug development, with a focus on Phase II trials*. J Biopharm Stat, 2009. **19**(3): p. 556-62.

IDSC Publications – April 25, 2012

20. Schilsky, R.L., et al., *Development and use of integral assays in clinical trials*. Clin Cancer Res, 2012. **18**(6): p. 1540-6.
21. Seymour, L., *Controversies in the Design of Phase II Clinical Trials*. Clinical Advances in Hematology & Oncology, 2010. **8**(2): p. 95-97.
22. Seymour, L., et al., *The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee*. Clin Cancer Res, 2010. **16**(6): p. 1764-9.
23. Shankar, L.K., et al., *Considerations for the use of imaging tools for phase II treatment trials in oncology*. Clin Cancer Res, 2009. **15**(6): p. 1891-7.
24. Takebe, N. and S.P. Ivy, *Controversies in cancer stem cells: targeting embryonic signaling pathways*. Clin Cancer Res, 2010. **16**(12): p. 3106-12.
25. Weber, J.S., et al., *White Paper on Adoptive Cell Therapy for Cancer with Tumor Infiltrating Lymphocytes: a report of the CTEP Subcommittee on Adoptive Cell Therapy*. Clin Cancer Res, 2011.
26. Williams, P.M., et al., *Bridging the gap: moving predictive and prognostic assays from research to clinical use*. Clin Cancer Res, 2012. **18**(6): p. 1531-9.

Submitted:

1. Farooki, A., N. L. Busaidy, et al. (accepted, prepub 2012). "*Management of Metabolic Effects (Hyperlipidemia and Hyperglycemia) Associated with Anticancer Agents Targeting the PI3K-Akt-mTOR (PAM) Pathway*." Journal of Clinical Oncology.